Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Council Agrees Compromise Position On Joint Clinical Assessments

Industry Split On Whether It’s Progress Or A Letdown

Executive Summary

The Alliance For Regenerative Medicines is calling for advanced therapies to be given greater priority where joint clinical assessments are concerned.

You may also be interested in...



Breakthrough Agreement On EU HTA Regulation “Falls Short”

The European Parliament and EU Council have reached an agreement on taking forward proposals for greater cooperation on health technology assessments.

EU Council Calls for Discussions On New Pricing Mechanisms

Transparency on pricing and cost calculations could improve and inform public policy on medicines access, say EU health ministers.

Drug Pricing Shake Up Likely In Germany

The umbrella organization for public insurers is also expected to publish its own suggestions on how to cut spending on pharmaceuticals, including interim prices for conditionally approved drugs.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel